Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibodies and Vaccines Target RBD of SARS-CoV-2

22 Apr 2021

Abstract excerpt

The novel human coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which gives rise to the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. On March 11, 2020, the WHO had officially announced COVID-19 as a pandemic. Therefore, it is vital to find effective and safe neutralizing antibodies and vaccines for COVID-19. The critical neutralizing domain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33968996
DOI: 10.3389/fmolb.2021.671633

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibodies and Vaccines Target RBD of SARS-CoV-2PMID 33968996Read ↗

Receptor-binding domain as a target for developing SARS vaccines.Semantic proximity Read ↗

A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding DomainSemantic proximity Read ↗

Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies.Semantic proximity Read ↗

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodiesSemantic proximity Read ↗

Isolation and characterization of neutralizing monoclonal antibodies from a large panel of murine antibodies against RBD of the SARS-CoV-2 Spike proteinSemantic proximity Read ↗

SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1Semantic proximity Read ↗

A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBDSemantic proximity Read ↗

Neutralizing antibodies for the prevention and treatment of COVID-19Semantic proximity Read ↗

Neutralizing antibodies targeting SARS-CoV-2 spike proteinSemantic proximity Read ↗

The recombinant subunit vaccine RBD-Fc, consisting of SARS-CoV-2 RBD and human IgG Fc as an immunopotentiator, elicits robust neutralizing antibody responses against SARS-CoV-2 infectionSemantic proximity Read ↗

Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic AntibodiesSemantic proximity Read ↗

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.